金吾财讯 | 礼来公司（LLY）两款减肥疗法的每周处方量不及诺和诺德（NVO）竞品Wegovy，受此影响，礼来股价在盘前交易中跌1.82%。
分析师指出，截至4月17日当周，礼来Zepbound的总处方量较前一周下降约2%，而同期诺和诺德Wegovy注射剂处方量环比上升7%。当前糖尿病和肥胖症注射剂领域整体处方增长放缓，但Wegovy注射剂仍保持显著增长。
礼来新推出的口服减肥药物Foundayo，上市首周处方总量为3707份。相比之下，诺和诺德口服版Wegovy上市首周处方量约为18410份，Foundayo首周处方量仅为前者的20%。
分析师表示，不应仅凭单周上市数据评判Foundayo的市场表现，但投资者会密切关注这一处方量差距，这种落差大概率导致礼来当日股价表现疲软。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.